UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000011094
Receipt number R000012810
Scientific Title Anti-vascular endothelial growth factor therapy for ocular diseases with neovascularization
Date of disclosure of the study information 2013/07/15
Last modified on 2018/01/04 13:06:42

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Anti-vascular endothelial growth factor therapy for ocular diseases with neovascularization

Acronym

Anti-VEGF therapy for ocular neovascularization

Scientific Title

Anti-vascular endothelial growth factor therapy for ocular diseases with neovascularization

Scientific Title:Acronym

Anti-VEGF therapy for ocular neovascularization

Region

Japan


Condition

Condition

choroidal neovascularization
diabetic retinopathy
retinal vein occulusion
neovascular glaucoma
retinopathy of prematurity
central serous chorioretinopathy

Classification by specialty

Ophthalmology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To demonstrate the efficacy and safety of intravitreal injection of bevacizumab for ocular neovascular diseases.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase

Phase I,II


Assessment

Primary outcomes

Change in the visual acuity at 12 months from the initial treatment

Key secondary outcomes

The number of injections required over 12 months of follow-up. The presence or absence of complications.


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Intravitreal injection of Bevacizumab

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

The presence of active lesions of
1)myopic or secondary choroidal neovascularization
2)diabetic retinopathy
3)retinal vein occulusion
4)neovascular glaucoma
5)retinopathy of prematurity
6)central serous chorioretinopathy

Key exclusion criteria

1)high risk of stroke or myocardial infarction
2)systemic diseases with vessel occulusions
3)ocular infection

Target sample size

510


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Shigeru Honda

Organization

Kobe University Graduate school of Medicine

Division name

Ophthalmology

Zip code


Address

7-5-2 Kusunoki-cho, Chuo-ku, Kobe 650-0017 Japan

TEL

078-382-5111

Email



Public contact

Name of contact person

1st name
Middle name
Last name Shigeru Honda

Organization

Kobe University Graduate school of Medicine

Division name

Ophthalmology

Zip code


Address

7-5-2 Kusunoki-cho, Chuo-ku, Kobe 650-0017 Japan

TEL

078-382-5111

Homepage URL


Email



Sponsor or person

Institute

Kobe University Graduate school of Medicine

Institute

Department

Personal name



Funding Source

Organization

Kobe University Graduate school of Medicine

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2013 Year 07 Month 15 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2013 Year 06 Month 04 Day

Date of IRB


Anticipated trial start date

2013 Year 07 Month 01 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2013 Year 07 Month 02 Day

Last modified on

2018 Year 01 Month 04 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000012810


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name